Human interleukin-2 (I)

also known as IL-2 · Interleukin-2

Developed for: chronic idiopathic urticaria
Investigated by: First Affiliated Hospital of Guangxi Medical University · Fujian Medical University Union Hospital · Second Affiliated Hospital of Guangzhou Medical University · Second Xiangya Hospital of Central South University · The First People's Hospital of Changde City · The Third People's Hospital of Hangzhou
+4 more
· Third Affiliated Hospital, Sun Yat-Sen University · Tongji Hospital · West China Hospital · Xiangya Hospital of Central South University

today NCT06924762 · Ph 2/3

2026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT06924762	Mar → Dec 2025 overdue	chronic idiopathic urticaria	Second Xiangya Hospital of Central South University	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Human interleukin-2 (I)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06924762 ↗
Known as	IL-2	“Recent studies have shown that human IL-2 (Interleukin-2) can be effective in a proportion of CSU patients refractory to antihistamine treatment, without significant side effects.” NCT06924762 ↗
Known as	Interleukin-2	“Recent studies have shown that human IL-2 (Interleukin-2) can be effective in a proportion of CSU patients refractory to antihistamine treatment, without significant side effects.” NCT06924762 ↗
Route	Intramuscular	“intramuscular injection of human interleukin-2 (I) will be added.” NCT06924762 ↗